Ema Lupšić

Ema Lupšić graduated with a degree in Biology from the University of Belgrade in 2019. She furthered her education by pursuing a master's degree at Sorbonne University in Paris, specializing in Molecular Biology of the Cell, in 2020. Since 2021, Ema is enrolled in doctoral studies at the Faculty of Biology of the University of Belgrade in the field of physiology - module ,,Translational research in neurobiology and biomedicine”. She achieved the title of research trainee on October 29, 2021 and since 2022, Ema has been employed at the Institute for Biological Research, "Siniša Stanković," within the Department of Neurobiology. Ema actively contributes to two projects funded by the Science Fund of the Republic of Serbia. The first project, "PhotoSCLART," revolves around the development of nature-inspired photoresponsive anticancer agents - sclareol and artemisinin derivatives in cancer multidrug-resistance models, serving as a cornerstone for the theranostic approach. Additionally, she is involved in the "TargetedResponse" project, which focuses on functional diagnostics in Non-Small Cell Lung Carcinoma—a novel approach aimed at enhancing personalized therapy for Serbian patients. Furthermore, Ema is member of the Serbian Academy of Sciences (SANU) project team titled "Biomedical potential of diterpenes newly isolated from latex of milkweeds (Euphorbia L.) wild-growing in Serbia." She actively participated in academic conferences, including the sixth congress of SDIR "From Collaboration to Innovation in Cancer Research" in 2023, the eighth congress of the Serbian Neuroscience Society in Belgrade (Serbia) in 2023, and the annual "STRATAGEM" conference in 2021 in Prague (Czech Republic). Ema Lupšić is affiliated with several professional societies, including the Serbian Society of Cancer Researchers, the Biochemical Society of Serbia, and the Society for Neuroscience of Serbia.